CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 250 enrolled
Drug / intervention
Ixekizumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05855967
NCT05855967Phase 4Completed
CompareCT.gov

A 24-Week Multicenter, Open-label, Single-arm, Phase 4 Study to Evaluate the Safety of Ixekizumab in Patients With Moderate-to-Severe Plaque Psoriasis or Active Psoriatic Arthritis in India

Eli Lilly and Company·interventional·Posted May 12, 2023·Updated Aug 22, 2025

In Brief

A Phase 4 clinical trial evaluating Ixekizumab for Plaque Psoriasis and Psoriatic Arthritis. Completed, enrolled 250 participants across 14 sites.

Detailed Summary

The main purpose of this study is to investigate the safety and tolerability of ixekizumab in participants in India with moderate-to-severe plaque psoriasis (PsO) or active psoriatic arthritis (PsA)

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPlaque Psoriasis, Psoriatic Arthritis
CountriesIndia
Collaborators--

Timeline

Phase 4CompletedFinished
202420252026
First PostedMay 12, 2023
Enrollment StartJun 27, 2023
Primary CompletionAug 8, 2024
Study CompletionSep 23, 2024
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 3.1 years ago

Interventions

Ixekizumabdrug

Administered SC